Non-ST Elevation MI: How Long Do We Have for A Coronary Angiography?

This summary discusses the early invasive strategy and the risk of mortality in non-ST-elevation AMI.


Over the past 2 decades, mortality and complications rates have seen a significant reduction thanks to technological and pharmaceutical development, and the increasing experience of health teams. This is especially true when we look at the use of coronary angiography withing 72 hours of symptom onset; in these cases, mortality risk has gone from 3 to 6 months. 

IAM sin elevación del ST: ¿cuánto tiempo tenemos para realizar una coronariografía?

At present, the information is contradicting when it comes to an early invasive strategy. Even though some registries and randomized studies have not shown improvement, this might be the result of different factors, such as the time between symptom onset and the coronary angiography. 

The KAMIR-NIH with 5856 non-ST myocardial infarction patients (NSTEMI) was analyzed: 3919 of these patients had a symptom onset to catheter time (StC) of <48 hours (66.9%) and 1937 a >48-hr StC.

Primary end point was all cause mortality at 3 years and secondary end point was the composite of all cause death, repeat MI or rehospitalization for cardiac failure at 3 years. 

Mean age was 64 and over 70% were men. 

Read also: Is Rehospitalization a Relevant Factor after Aortic Valve Replacement?

Patients presenting <48 hr. StC more often presented hypertension, diabetes, kidney function deterioration, MI, typical angina, angina after the first episode, less cardiac failure, lower GRACE score and better left ventricular function. 

StC was 17.5 hrs. vs 90.8 hrs.

The presence of left main severe stenosis was 5.6%, 3 vessel disease 19%, 2 vessel lesion 28% and one vessel lesion 45%. PCI was done in 85% of cases, CABG in 1.5% and the rest received optimal medical treatment.   

Primary end point at 3 years was 7.3% vs. 13.4% (3-year adjusted HR: 0.76; 95% CI:0.64-0.91; P = 0.002) for <48 hr. StC patient vs >48 hr StC patients respectively. Secondary end point was also in favor of <48 hr StC (12.2% vs. 19.6% 3-year adjusted HR: 0.84; 95% CI: 0.73-0.96; P=0.015).

Read also: Is it Possible to Reduce DAPT Time in Diabetic Patients?

The use of emergency systems was associated to <48 hr StC and lower mortality.

Conclusion

An early invasive strategy based on symptom to catheter time was associated to lower all-cause mortality risk in NSTEMI patients. Seeing as this is a prospective registry, this conclusion should be considered as hypothesis generator to encourage future research. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Early Invasive Strategy Based on the Time of Symptom Onset of Non-ST-Segment Elevation Myocardial Infarction.

Reference: SungA Bae, et al. J Am Coll Cardiol Intv 2023;16:64–75.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...